|
 |
INVESTOR
RELATIONS •
OVERVIEW
- Alzheimer’s disease is a “blockbuster” indication with significant forecasted growth
- Experienced management team and scientific advisory board
- Identify and develop novel drug candidates for
neurodegenerative diseases
- Best-in-class therapeutics
- Significant clinical improvements versus current treatments
- Leverage 3rd party and strategic alliances for cost effective development
- Seek to license compounds at optimal point:
- Minimize development risk
- Maximize shareholder return
|
|
 |
Contact
News